MedPath

Culturally Tailored Nurse Coaching Study for Cancer Symptom Management

Not Applicable
Completed
Conditions
Symptom Cluster
Chemotherapy Effect
Dehydration
Quality of Life
Self Efficacy
Registration Number
NCT04874584
Lead Sponsor
University of Miami
Brief Summary

The purpose of the study is to see whether or not a telephone/ text message intervention, delivered by a registered nurse, is helpful in managing symptoms and can also prevent dehydration caused by chemotherapy treatment when given together for patients with metastatic breast, colon, lung or prostate cancer.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
34
Inclusion Criteria
  1. Eligible for Chemotherapy for the first time (Previous & Ongoing hormonal only treatment allowed OR Neoadjuvant & Adjuvant chemotherapy regimens with 2+ drugs allowed)
  2. > 18 years old
  3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
  4. There are no life expectancy restrictions
  5. Women of child-bearing potential are allowed in the study as long as they are eligible for the chemotherapy treatment.
  6. Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria
  1. Patients on immunotherapy only will be excluded
  2. Previous chemotherapy
  3. Under 18 years old
  4. Medically Diagnosed with a Cognitive Impairment. Rationale for excluding people with cognitive impairment is that they would not be able to fully participate in the self-management care aspects of the intervention via the telephone, nor provide informed consent.
  5. No access to a telephone
  6. Blind or Deaf; If subject is Hearing-impaired or illiterate, then the subject may have a family member participate as a telecommunication surrogate with them in the study

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Change in MDASI scoresbaseline, up to 12 weeks

MD Anderson Symptom Inventory (MDASI) is a 19 item scale with a score range from 0-10 per symptom question that measures symptom severity plus symptom interference combined to measure total symptom burden. The higher score indicates worsening of symptoms.

Incidents of dehydrationup to 12 weeks

Incidents of unscheduled medical visits for IV hydration

Secondary Outcome Measures
NameTimeMethod
change in Partners in Health Scale (PIHS) scoresbaseline, up to 12 weeks

The PIHS is a 12 item scale with a score range from 0-8 per question that measures symptoms self-management. The higher score indicates better symptom self-management.

Change in FACT-C Scoresbaseline, up to 12 weeks

Health Related Quality of Life (HRQoL) will be measured by the Functional Assessment of Cancer Therapy -Colon (FACT-C). FACT-C has a total scoring of 0-144 with the higher scoring indicating better HRQoL.

change in Chronic Disease Self-Efficacy Scale (CDSES) scoresbaseline, up to 12 weeks

The CDSES is a 10 item scale with a score range from 0-10 per symptom question that measures perceived self-efficacy. The higher score indicates better perceived self-efficacy.

Change in FACT-B Scoresbaseline, up to 12 weeks

Health Related Quality of Life (HRQoL) will be measured by the Functional Assessment of Cancer Therapy -Breast (FACT-B). FACT-B has a total scoring of 0-148 with the higher scoring indicating better HRQoL.

Change in FACT-P Scoresbaseline, up to 12 weeks

Health Related Quality of Life (HRQoL) will be measured by the Functional Assessment of Cancer Therapy -Prostate (FACT-P). FACT-P has a total scoring of 0-156 with the higher scoring indicating better HRQoL.

Change in FACT-LC Scoresbaseline, up to 12 weeks

Health Related Quality of Life (HRQoL) will be measured by the Functional Assessment of Cancer Therapy -Lung Cancer (FACT-LC). FACT-LC has a total scoring of 0-144 with the higher scoring indicating better HRQoL.

Percentage of completed call or text messageup to 12 weeks

Feasibility will be reported as a percentage of completed calls or text messages.

Trial Locations

Locations (1)

University of Miami Sylvester Comprehensive Cancer Ctr.

🇺🇸

Miami, Florida, United States

University of Miami Sylvester Comprehensive Cancer Ctr.
🇺🇸Miami, Florida, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.